<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369745</url>
  </required_header>
  <id_info>
    <org_study_id>Z102-008</org_study_id>
    <nct_id>NCT01369745</nct_id>
  </id_info>
  <brief_title>A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis</brief_title>
  <acronym>Synergy</acronym>
  <official_title>A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zalicus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zalicus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thus study will test an experimental drug called Z-102 (combination of prednisolone and
      dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study was to demonstrate the efficacy of Z102 (2.7 mg
      prednisolone/360 mg dipyridamole) versus placebo on the Disease Activity Score 28 using C
      reactive protein (DAS28-CRP) in subjects with rheumatoid arthritis at the study endpoint of
      12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in DAS28-CRP at 12 Weeks</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>The primary efficacy endpoint was the mean change in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12.
The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of &lt;3.2 suggests a low level of disease activity, while a score of &gt;5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP Individual Components at 12 Weeks</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The mean change in the individual components of the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12 which included individual assessment of Tender Joint Count (28-joint assessment), Swollen Joint Count (28-joint assessment), Patient Global Assessment of Disease Activity and absolute CRP level. In each case, higher scores indicate more disease activity.
The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of &lt;3.2 suggests a low level of disease activity, while a score of &gt;5.1 suggests a high level of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving ACR20, ACR50 and ACR70 at 12 Weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>The American College of Rheumatology (ACR) 20 is a widely accepted composite index of improvement in RA proposed by the ACR (Fransen and van Riel 2009). ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures:Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ) (Arnet 1988 and Felson 1995), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Assessment of Fatigue (MAF) at Week 12</measure>
    <time_frame>week 12</time_frame>
    <description>The Multidimensional Assessment of Fatigue (MAF) scale contains 16 items and measures four dimensions of fatigue: severity (#1-2), distress (#3), degree of interference in activities of daily living (#4-14), and timing (#15-16). Fourteen items contain numerical rating scales (#1-14) and two items have multiple-choice responses (#15-16). Respondents are asked to reflect on fatigue patterns for the past week.
To calculate the Global Fatigue Index (GFI): Convert item #15 to a 0-10 scale by multiplying each score by 2.5 and then sum items #1, 2, 3, average #4-14, and newly scored item #15.
Scores range from 1 (no fatigue) to 50 (severe fatigue). Do not assign a score to items #4-14 if respondent indicated they &quot;do not do any activity for reasons other than fatigue.&quot; If respondents select no fatigue on item #1, assign a zero to items #2-16. Item #16 is not included in the Global Fatigue Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Failure (Days)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Patients will be monitored for addition of any DMARD or withdrawal due to flare. The time to failure is defined as the duration of study participation (in days) until a qualifying event or completion of study treatment, whichever comes first.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone 2.7 mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dipyridamole 360 mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone 5 mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z102 (2.7/360)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 2.7 mg daily</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dipyridamole</intervention_name>
    <description>dipyridamole 360 mg daily</description>
    <arm_group_label>dipyridamole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 5 mg daily</description>
    <arm_group_label>prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z102</intervention_name>
    <description>Prednisolone 2.7 mg plus dipyridamole 360 mg daily</description>
    <arm_group_label>Z102 (2.7/360)</arm_group_label>
    <other_name>prednisolone</other_name>
    <other_name>dipyridamole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the ACR / EULAR criteria for classification of RA

          -  Have moderate to severe RA, defined as involving a minimum (≥6 total swollen and ≥6
             total tender) of the 28 joints assessed

          -  Have screening CRP levels of at least 0.6 mg/dl and a DAS28-CRP score ≥4.5

          -  Have been on a stable dose of conventional DMARD therapy for at least 90 days without
             dosage adjustment or modification and should be able to maintain the same dose of
             conventional DMARD therapy during study participation (with or without glucocorticoid
             therapy

        Exclusion Criteria:

          -  Treatment-refractory patients are excluded

          -  Has active cardiovascular disease, unless well controlled by appropriate treatment for
             a minimum of 3 months prior to screening

          -  Is taking aspirin for reasons other than for cardiovascular prophylaxis or their total
             daily dose is greater than 325 mg

          -  Is currently taking steroids at a daily prednisone dose, or the equivalent, of &gt;10 mg

          -  Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given
             at least 6 weeks prior to entering the study

          -  The need to continue the use of one or multiple NSAID's at the same time, or the use
             of acetaminophen on a chronic basis

          -  All opiate use is prohibited

          -  Use of any other medications or herbs used for the treatment of pain is prohibited

          -  Patients with a history of or currently active tuberculosis as per specific country
             guidelines are excluded

          -  Has uncontrolled diabetes mellitus as defined by a serum glucose &gt;126 mg/dl

          -  Knowingly has HIV infection or hepatitis

          -  Has undergone administration of any investigational drug within 30 days of study
             initiation

          -  All biologic agents are excluded for 90 days prior to Screening and throughout the
             study.

          -  Has undergone administration of rituximab or any B-cell depleting investigational
             drugs within 6 months of study initiation

          -  Has had a history of alcohol or drug abuse within the past 2 years

          -  Has a history of hypersensitivity to glucocorticoids and/or dipyridamole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Lee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Zalicus, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zalicus Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>February 10, 2014</results_first_submitted>
  <results_first_submitted_qc>March 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2014</results_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Moderate to severe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 294 subjects entered the titration phase. Of these, 258 subjects completed the titration phase, were randomized to treatment, received at least one dose of study drug and constitute the safety population. Of these, 252 subjects provided at least one post-baseline measurement of the primary endpoint and constitute the efficacy population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prednisolone</title>
          <description>Prednisolone 2.7 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Dipyridamole</title>
          <description>dipyridamole 360 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Prednisone</title>
          <description>Prednisone 5 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>Z102</title>
          <description>2.7 mg prednisolone plus 360 mg dipyridamole once daily</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>placebo once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="84"/>
                <participants group_id="P5" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>population randomized to double blind phase of study and recieved at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Prednisolone</title>
          <description>Prednisolone 2.7 mg once daily The trial would progress from Stage 1 to Stage 2 if the posterior probability that Z102 is superior to placebo was greater than 0.975.</description>
        </group>
        <group group_id="B2">
          <title>Dipyridamole</title>
          <description>dipyridamole 360 mg once daily The trial would progress from Stage 2 to Stage 3 if the posterior probability that Z102 is superior to dipyridamole was greater than 0.975.</description>
        </group>
        <group group_id="B3">
          <title>Prednisone</title>
          <description>Prednisone 5 mg once daily The trial would progress from Stage 2 to Stage 4 if the posterior probability that Z102 is superior to prednisolone 2.7 was greater than 0.975.</description>
        </group>
        <group group_id="B4">
          <title>Z102</title>
          <description>prednisolone 2.7 mg plus dipyridamole 360 mg once daily The trial would progress from Stage 3 to Stage 5 if the posterior probability that Z102 is superior to prednisolone 2.7 was greater than 0.975.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>placebo once daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="84"/>
            <count group_id="B5" value="83"/>
            <count group_id="B6" value="258"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="12.69"/>
                    <measurement group_id="B2" value="55.9" spread="9.35"/>
                    <measurement group_id="B3" value="55.5" spread="9.82"/>
                    <measurement group_id="B4" value="54.5" spread="11.53"/>
                    <measurement group_id="B5" value="53.7" spread="12.44"/>
                    <measurement group_id="B6" value="54.6" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28-CRP at 12 Weeks</title>
        <description>The primary efficacy endpoint was the mean change in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12.
The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of &lt;3.2 suggests a low level of disease activity, while a score of &gt;5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.</description>
        <time_frame>baseline to week 12</time_frame>
        <population>The efficacy analysis population includes all 252 subjects who received at least one dose of study drug after randomization and who provided at least one post-baseline measurement of the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Prednisolone 2.7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Dipyridamole</title>
            <description>dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Prednisone</title>
            <description>Prednisone 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Z102</title>
            <description>prednisolone 2.7 mg plus dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP at 12 Weeks</title>
          <description>The primary efficacy endpoint was the mean change in Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12.
The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of &lt;3.2 suggests a low level of disease activity, while a score of &gt;5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.</description>
          <population>The efficacy analysis population includes all 252 subjects who received at least one dose of study drug after randomization and who provided at least one post-baseline measurement of the primary endpoint</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.147" spread="0.235"/>
                    <measurement group_id="O2" value="-0.813" spread="0.216"/>
                    <measurement group_id="O3" value="-1.237" spread="0.296"/>
                    <measurement group_id="O4" value="-0.907" spread="0.149"/>
                    <measurement group_id="O5" value="-0.538" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP Individual Components at 12 Weeks</title>
        <description>The mean change in the individual components of the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12 which included individual assessment of Tender Joint Count (28-joint assessment), Swollen Joint Count (28-joint assessment), Patient Global Assessment of Disease Activity and absolute CRP level. In each case, higher scores indicate more disease activity.
The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of &lt;3.2 suggests a low level of disease activity, while a score of &gt;5.1 suggests a high level of disease activity.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Prednisolone 2.7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Dipyridamole</title>
            <description>dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Prednisone</title>
            <description>Prednisone 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Z102</title>
            <description>prednisolone 2.7 mg plus dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP Individual Components at 12 Weeks</title>
          <description>The mean change in the individual components of the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) from baseline to Week 12 which included individual assessment of Tender Joint Count (28-joint assessment), Swollen Joint Count (28-joint assessment), Patient Global Assessment of Disease Activity and absolute CRP level. In each case, higher scores indicate more disease activity.
The DAS28-CRP is a composite measure of inflammation in Rheumatoid Arthritis and incorporates a tender and swollen joint count, CRP and Patient Global Assessment of Disease Activity expressed in a Gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of &lt;3.2 suggests a low level of disease activity, while a score of &gt;5.1 suggests a high level of disease activity.</description>
          <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving ACR20, ACR50 and ACR70 at 12 Weeks</title>
        <description>The American College of Rheumatology (ACR) 20 is a widely accepted composite index of improvement in RA proposed by the ACR (Fransen and van Riel 2009). ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures:Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ) (Arnet 1988 and Felson 1995), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.</description>
        <time_frame>Week 12</time_frame>
        <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Prednisolone 2.7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Dipyridamole</title>
            <description>dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Prednisone</title>
            <description>Prednisone 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Z102</title>
            <description>prednisolone 2.7 mg plus dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving ACR20, ACR50 and ACR70 at 12 Weeks</title>
          <description>The American College of Rheumatology (ACR) 20 is a widely accepted composite index of improvement in RA proposed by the ACR (Fransen and van Riel 2009). ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures:Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ) (Arnet 1988 and Felson 1995), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.</description>
          <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multidimensional Assessment of Fatigue (MAF) at Week 12</title>
        <description>The Multidimensional Assessment of Fatigue (MAF) scale contains 16 items and measures four dimensions of fatigue: severity (#1-2), distress (#3), degree of interference in activities of daily living (#4-14), and timing (#15-16). Fourteen items contain numerical rating scales (#1-14) and two items have multiple-choice responses (#15-16). Respondents are asked to reflect on fatigue patterns for the past week.
To calculate the Global Fatigue Index (GFI): Convert item #15 to a 0-10 scale by multiplying each score by 2.5 and then sum items #1, 2, 3, average #4-14, and newly scored item #15.
Scores range from 1 (no fatigue) to 50 (severe fatigue). Do not assign a score to items #4-14 if respondent indicated they &quot;do not do any activity for reasons other than fatigue.&quot; If respondents select no fatigue on item #1, assign a zero to items #2-16. Item #16 is not included in the Global Fatigue Index.</description>
        <time_frame>week 12</time_frame>
        <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Prednisolone 2.7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Dipyridamole</title>
            <description>dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Prednisone</title>
            <description>Prednisone 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Z102</title>
            <description>prednisolone 2.7 mg plus dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Multidimensional Assessment of Fatigue (MAF) at Week 12</title>
          <description>The Multidimensional Assessment of Fatigue (MAF) scale contains 16 items and measures four dimensions of fatigue: severity (#1-2), distress (#3), degree of interference in activities of daily living (#4-14), and timing (#15-16). Fourteen items contain numerical rating scales (#1-14) and two items have multiple-choice responses (#15-16). Respondents are asked to reflect on fatigue patterns for the past week.
To calculate the Global Fatigue Index (GFI): Convert item #15 to a 0-10 scale by multiplying each score by 2.5 and then sum items #1, 2, 3, average #4-14, and newly scored item #15.
Scores range from 1 (no fatigue) to 50 (severe fatigue). Do not assign a score to items #4-14 if respondent indicated they &quot;do not do any activity for reasons other than fatigue.&quot; If respondents select no fatigue on item #1, assign a zero to items #2-16. Item #16 is not included in the Global Fatigue Index.</description>
          <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Failure (Days)</title>
        <description>Patients will be monitored for addition of any DMARD or withdrawal due to flare. The time to failure is defined as the duration of study participation (in days) until a qualifying event or completion of study treatment, whichever comes first.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>Prednisolone 2.7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Dipyridamole</title>
            <description>dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Prednisone</title>
            <description>Prednisone 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Z102</title>
            <description>prednisolone 2.7 mg plus dipyridamole 360 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Failure (Days)</title>
          <description>Patients will be monitored for addition of any DMARD or withdrawal due to flare. The time to failure is defined as the duration of study participation (in days) until a qualifying event or completion of study treatment, whichever comes first.</description>
          <population>Because the study never progressed past the first stage of the adaptive randomization, the number of subjects who were allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg treatment arms was insufficient (underpowered) to allow analysis of the secondary objectives.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the time of consent through the end of study visit at 12 weeks.</time_frame>
      <desc>Adverse events are reported for the safety population of 258 subjects randomized to the double blind study phase and who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prednisolone</title>
          <description>Prednisolone 2.7 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Dipyridamole</title>
          <description>dipyridamole 360 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Prednisone</title>
          <description>Prednisone 5 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>Z102</title>
          <description>prednisolone 2.7 mg plus dipyridamole 360 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Haemolytic Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteric Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal Upper Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash Pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study did not progress past the first stage of adaptive randomization. The number of subjects allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg arms was insufficient to allow analysis of the secondary objectives.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret Lee,PhD</name_or_title>
      <organization>Zalicus</organization>
      <phone>617-301-7142</phone>
      <email>mlee@zalicus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

